# Orilissa (elagolix sodium) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/elagolix

> The FDA approved Orilissa (elagolix sodium), sponsored by AbbVie Inc. (ABBV), on July 23, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Orilissa (elagolix sodium) |
| Codes | ABT-620 |
| Sponsor | AbbVie Inc. (ABBV) https://sec-api.dev/companies/abbv/catalysts |
| Indications | [Endometriosis](https://sec-api.dev/indications/endometriosis) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### July 23, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210450 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180723, review_priority PRIORITY; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22

### February 1, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA210450 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22
- openFDA Drugs@FDA: "NDA210450 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22
- openFDA Drugs@FDA: "NDA210450 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometriosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04333576

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometriosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." https://clinicaltrials.gov/study/NCT04333576

## Same indication

- [OG-6219](https://sec-api.dev/pdufa/og-6219) (OGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/elagolix.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Orilissa (elagolix sodium) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/elagolix

```bibtex
@misc{secapidev_pdufa_elagolix_20261116,
  title        = {Orilissa (elagolix sodium) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/elagolix}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_elagolix_20261116","title":"Orilissa (elagolix sodium) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/elagolix","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
